Descrição
Made available in DSpace on 2022-04-29T08:41:27Z (GMT). No. of bitstreams: 0 Previous issue date: 2022-03-01
Background: Several therapies have been used or proposed for the treatment of COVID-19, although their effectiveness and safety have not been properly evaluated. The purpose of this document is to provide recommendations to support decisions about the drug treatment of outpatients with COVID-19 in Brazil. Methods: A panel consisting of experts from different clinical fields, representatives of the Brazilian Ministry of Health, and methodologists (37 members in total) was responsible for preparing these guidelines. A rapid guideline development method was used, based on the adoption and/or adaptation of recommendations from existing international guidelines combined with additional structured searches for primary studies and new recommendations whenever necessary (GRADE-ADOLOPMENT). The rating of quality of evidence and the drafting of recommendations followed the GRADE method. Results: Ten technologies were evaluated, and 10 recommendations were prepared. Recommendations were made against the use of anticoagulants, azithromycin, budesonide, colchicine, corticosteroids, hydroxychloroquine/chloroquine alone or combined with azithromycin, ivermectin, nitazoxanide, and convalescent plasma. It was not possible to make a recommendation regarding the use of monoclonal antibodies in outpatients, as their benefit is uncertain and their cost is high, with limitations of availability and implementation. Conclusion: To date, few therapies have demonstrated effectiveness in the treatment of outpatients with COVID-19. Recommendations are restricted to what should not be used, in order to provide the best treatment according to the principles of evidence-based medicine and to promote resource savings by aboiding ineffective treatments.
Hospital Moinhos de Vento, Rio Grande do Sul
Instituto de Avaliação de Tecnologia em Saúde (IATS) Universidade Federal do Rio Grande do Sul, Rio Grande do Sul
Department of Health Research Methods Evidence and Impact McMaster University
UNESP – Faculdade de Medicina Departamento de Infectologia
Serviço de Infectologia e Controle de Infecção do Hospital Moinhos de Vento, Rio Grande do Sul
Departamento de Medicina Interna Universidade Federal do Rio Grande do Sul, Rio Grande do Sul
Serviço de Infectologia do Hospital de Clinicas de Porto Alegre, Rio Grande do Sul
Hospital das Clínicas da Faculdade de Medicina da Universidade de São Paulo, São Paulo
Universidade Federal da Bahia (UFBA), Bahia
Corpometria Institute, Brasília
Escola Paulista de Medicina (UNIFESP-EPM), São Paulo
Universidade Federal do Pará
Instituto do Coração Hospital das Clinicas HCFMUSP Faculdade de Medicina Universidade de São Paulo, São Paulo
Hospital Sírio-Libanes, São Paulo
Hospital das Clínicas da Faculdade de Medicina de Botucatu (HCFMB/UNESP), São Paulo
Departamento de Saúde Coletiva da Universidade Federal de Santa Maria (UFSM), Rio Grande do Sul
Serviço de Atenção Domiciliar do Hospital Universitário de Santa Maria, Rio Grande do Sul
Universidade Federal de Santa Catarina (UFSC)
Instituto de Infectologia Emílio Ribas
Associação Beneficência Portuguesa de São Paulo (BP), São Paulo
UNESP – Faculdade de Medicina Departamento de Infectologia
Hospital das Clínicas da Faculdade de Medicina de Botucatu (HCFMB/UNESP), São Paulo
